The impact of bisphosphonates on oral health: Lessons from the past and opportunities for the future

Annals of the New York Academy of Sciences

Volumn 1218, Issue 1, 2011, Pages 55-61

  Zavras, Athanasios I ^a,b  

^a New York Presbyterian Hospital   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Biosphosphonates; Epidemiology; Oral health

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; RISEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; DISEASE DURATION; HUMAN; INCIDENCE; JAW OSTEONECROSIS; MORBIDITY; OSTEOPOROSIS; PERIODONTAL DISEASE; RISK ASSESSMENT; SURVIVAL RATE; TOOTH EXTRACTION; TREATMENT OUTCOME;

EID: 79551527990     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05876.x     Document Type: Article

References (38)

1. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. 2007. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral. Maxillofac. Surg. 65: 369-376.
2. Cartsos, V.M., A. Seamanduras, S. Koo & A.I. Zavras 2009. Implications of bisphosphonate use in dentistry. Analecta Periodontologica 20: 1-15.
3. Eberhardt, C., B. Habermann, S. Muller, et al 2007. The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model. J. Orthop. Sci. 12: 61-66.
4. Aspenberg, P. 2009. Bisphopshonates and implants. Acta Orthop. 80: 119-123.
5. Ferguson, S.J., J.D. Langhoff, K. Voelter, et al 2008. Biomechanical comparison of different surface modifications for dental implants. Int. J. Oral Maxillofac. Implants 23: 1037-1046.
6. Shabestari, G.O., Y.S. Shayesteh, A. Khojasteh, et al 2010. Implant placement in patients with oral bisphosphonate therapy: a case series. Clin. Implant Dent. Relat. Res. 12: 175-180.
7. Grant, B.T., C. Amenedo, K. Freeman & R.A. Kraut 2008. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J. Oral Maxillofac. Surg. 66: 223-230.
8. Bell, B.M. & R.E. Bell 2008. Oral bisphosphonates and dental implants: a retrospective study. J. Oral Maxillofac. Surg. 66: 1022-1024.
9. Kasai, T., M.A. Pogrel & M. Hossaini 2009. The prognosis for dental implants placed in patients taking oral bisphosphonates. J. Calif. Dent. Assoc. 37: 39-42.
10. Jeffcoat, M.K., G. Cizza, W.J. Shih, et al 2007. Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. J. Int. Acad. Periodontol. 9: 70-76.
11. Jeffcoat, M.K. 2006. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int. J. Oral Maxillofac. Implants 21: 349-353.
12. Ren, Y., J.C. Maltha, M.A. Van 't Hof & A.M. Kuijpers-Jagtman 2003. Age effect on orthodontic tooth movement in rats. J. Dent. Res. 82: 38-42.
13. Morse, C.A., A. Smith, L. Dennerstein, et al 1994. The treatment-seeking woman at menopause. Maturitas 18: 161-173.
14. Arlot, M.E., E. Sornay-Rendu, P. Garnero, et al 1997. Apparent pre-and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J. Bone Miner. Res. 12: 683-690.
15. Tyrovola, J.B. & M.N. Spyropoulos 2001. Effects of drugs and systemic factors on orthodontic treatment. Quintessence Int. 32: 365-371.
16. Miyajima, K., K. Nagahara & T. Iizuka 1996. Orthodontic treatment for a patient after menopause. Angle Orthod. 66: 173-178.
17. Schwartz, J.E. 2005. Ask us: some drugs affect tooth movement. Am. J. Orthod. Dentofacial Orthop. 127: 644.
18. Igarashi, K., H. Adachi, H. Mitani & H. Shinoda 1996. Inhibitory effect of the topical administration of a bisphosphonate (risedronate) on root resorption incident to orthodontic tooth movement in rats. J. Dent. Res. 75, 1644-1649.
19. Lee, K., H. Suriyama, S. Imoto & K. Tanne 2001. Effects of bisphosphonate on the remodeling of rat sagittal suture after rapid expansion. Angle Orthod. 71: 265-273.
20. Kim, T.W., Y. Yoshida, K. Yokoya & T. Sasaki 1999. An ultrastructural study of the effects of bisphosphonate administration on osteoclaststic bone resorption during relapse of experimentally moved rat molars. Am. J. Orthod. Dentofac. Orthop. 115: 645-652.
21. Sato, Y., H. Sakai, Y. Kobayashi, et al 2000. Bisphosphonate administration alters subcellular localization of vacuolar-Type H-ATPase and cathepsin K in osteoclasts during experimental movement of rat molars. Anat. Rec. 260: 72-80.
22. Liu, L., K. Igarashi, N. Haruyama, et al 2004. Effects of local administration of clodronate on orthodontic tooth movement and root resorption in rats. Eur. J. Orthod. 26: 469-473.
23. Liu, L., K. Igarashi, H. Kanzaki, et al 2006. Clodronate inhibits PGE2 production in compressed periodontal ligament cells. J. Dent. Res. 85: 757-760.
24. Pampu, A.A., D. Dolanmaz, H.H. Tüz & A. Karabacakoglu 2006. Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis. J. Oral Maxillofac. Surg. 64: 1232-1236.
25. MacMahon, B. & T.F. Pugh 1970. Epidemiology: Principles and Methods. Little Brown. Boston.
26. Wessel, J.H., T.B. Dodson & A.I. Zavras 2008. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J. Oral Maxillofac. Surg. 66: 625-631.
27. Bamias, A., E. Kastritis, C. Bamia, et al 2005. ONJ in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 23: 8580-8587.
28. Jadu, F., L. Lee, M. Pharoah, et al 2007. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann. Oncol. 18: 2015-2019.
29. Hoff, A.O., B.B. Toth, K. Altundag, et al 2008. The Frequency and risk factors associated with ONJ in cancer patients treated with intravenous bisphosphonate. J. Bone Min. Res. 23: 826-836.
30. Fehm, T., V. Beck, M. Banys, et al 2009. Bisphosphonate-induced ONJ (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gyn. Oncol. 112: 605-609.
31. Durie, B.G., M. Katz & J. Crowley 2005. ONJ and bisphosphonates [letter]. N. Engl. J. Med. 353: 99-100.
32. Woo, S.B., H. Mawardi & N. Treister 2009. Comments on "Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification". Oral Oncol. 45: 740.
33. Cartsos, V.M., S. Zhu & A.I. Zavras 2008. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714, 217 people. J. Am. Dent. Assoc. 139: 23-30.
34. Van Den Wyngaert, T., T. Claeys, M.T. Huizing, et al 2009. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann. Oncol. 20: 331-336.
35. Palaska, P.K., V. Cartsos & A.I. Zavras 2009. Bisphosphonates and time to osteonecrosis development. Oncologist 14: 1154-1166.
36. Allen, M.R. 2007. Animal models of osteonecrosis of the jaw. J. Musculoskelet Neuronal Interact 7: 358-360.
37. Sonis, S.T., B.A. Watkins, G.D. Lyng, et al 2009. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-treated osteonecrosis in cancer patients. Oral Oncol. 45: 164-172.
38. Hokugo, A., R. Christensen, E.M. Chung, et al 2010. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J. Bone Miner. Res. 25: 1337-1349.